17 assets in Renal Pelvis Urothelial Carcinoma

Therapeutic assets addressing Renal Pelvis Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Renal Pelvis Urothelial Carcinoma	National Cancer Institute (NCI)	P3	BB (68)
Cyclophosphamide Renal Pelvis Urothelial Carcinoma	Fred Hutchinson Cancer Center	P3	BB (67)
Pembrolizumab Renal Pelvis Urothelial Carcinoma	Fred Hutchinson Cancer Center	P3	BB (65)
Muamycin Renal Pelvis Urothelial Carcinoma	UroGen Pharma Ltd.	P3	B (63)
Atezolizumab Renal Pelvis Urothelial Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (62)
Relatlimab Renal Pelvis Urothelial Carcinoma	National Cancer Institute (NCI)	P2/3	B (62)
Durvalumab Renal Pelvis Urothelial Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (60)
Ipilimumab Renal Pelvis Urothelial Carcinoma	M.D. Anderson Cancer Center	P2	B (59)
Avelumab Renal Pelvis Urothelial Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (57)
Apsolol Renal Pelvis Urothelial Carcinoma	Emory University	P2	CCC (53)
Eribulin Monomethanesulfonate Renal Pelvis Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tocilizumab Renal Pelvis Urothelial Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Renal Pelvis Urothelial Carcinoma	Fred Hutchinson Cancer Center	P1/2	CCC (52)
Quemliclustat Renal Pelvis Urothelial Carcinoma	Fred Hutchinson Cancer Center	P1/2	CC (47)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Renal Pelvis Urothelial Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
xl495 Renal Pelvis Urothelial Carcinoma	Exelixis	P1	CC (43)
Cabozantinib Renal Pelvis Urothelial Carcinoma	National Cancer Institute (NCI)	P1	NR ()